Othman Maha, Gresele Paolo
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada.
School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada.
J Thromb Haemost. 2020 Aug;18(8):1855-1858. doi: 10.1111/jth.14827.
Platelet-type von Willebrand disease (PT-VWD) is a rare autosomal dominant platelet bleeding disorder, with 55 patients reported worldwide so far, probably frequently misdiagnosed. Currently, there are no clear guidelines for the diagnosis and management of PT-VWD and this may contribute to misdiagnosis and thus to inappropriate treatment of these patients. This report provides expert opinion-based consensus recommendations for the standardized diagnostic and management approach to PT-VWD. Tests essential in the diagnostic workup are platelet count and size, ristocetin-induced platelet agglutination with mixing studies, and sequencing of platelet GP1BA gene. Platelet transfusions and von Willebrand factor-rich concentrates (if VWF is low) are the most effective treatments. This consensus may help to avoid misdiagnosis and guide appropriate management of patients with this disease.
血小板型血管性血友病(PT-VWD)是一种罕见的常染色体显性血小板出血性疾病,目前全球报告的患者有55例,可能经常被误诊。目前,对于PT-VWD的诊断和管理尚无明确的指导方针,这可能导致误诊,进而对这些患者进行不恰当的治疗。本报告提供了基于专家意见的共识建议,用于PT-VWD的标准化诊断和管理方法。诊断检查中必不可少的测试包括血小板计数和大小、瑞斯托霉素诱导的血小板凝集及混合研究,以及血小板GP1BA基因测序。血小板输注和富含血管性血友病因子的浓缩物(如果血管性血友病因子水平低)是最有效的治疗方法。这一共识可能有助于避免误诊,并指导对该病患者进行适当的管理。